PubMed:23742877
Annnotations
PubmedHPO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 315-330 | HP_0012125 | denotes | prostate cancer |
T2 | 324-330 | HP_0002664 | denotes | cancer |
T3 | 629-644 | HP_0012125 | denotes | prostate cancer |
T4 | 638-644 | HP_0002664 | denotes | cancer |
chenxin_473849_800
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 109-145 | DP | denotes | castration-resistant prostate cancer |
T2 | 147-153 | DP | denotes | VENICE |
T3 | 210-219 | CI | denotes | Docetaxel |
T4 | 47-56 | CI | denotes | docetaxel |
T5 | 531-540 | CI | denotes | docetaxel |
T6 | 686-695 | CI | denotes | docetaxel |
T7 | 979-988 | CI | denotes | docetaxel |
T8 | 2617-2626 | CI | denotes | docetaxel |
T9 | 700-710 | CI | denotes | prednisone |
T10 | 61-71 | CI | denotes | prednisone |
T11 | 225-235 | CI | denotes | prednisone |
T12 | 545-555 | CI | denotes | prednisone |
T13 | 1039-1049 | CI | denotes | prednisone |
T14 | 2631-2641 | CI | denotes | prednisone |
T15 | 2838-2848 | CI | denotes | prednisone |
T16 | 1109-1120 | CI | denotes | aflibercept |
T17 | 516-527 | CI | denotes | aflibercept |
T18 | 2070-2081 | CI | denotes | aflibercept |
T19 | 2524-2535 | CI | denotes | aflibercept |
T20 | 0-11 | CI | denotes | Aflibercept |
T21 | 332-343 | CI | denotes | Aflibercept |
T22 | 1541-1552 | CI | denotes | Aflibercept |
T23 | 2585-2596 | CI | denotes | Aflibercept |
Linmchun_800_3
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 979-988 | CI | denotes | docetaxel |
T10 | 675-682 | CI | denotes | placebo |
T11 | 1556-1563 | CI | denotes | placebo |
T12 | 1541-1552 | CI | denotes | Aflibercept |
T13 | 2123-2130 | CI | denotes | placebo |
T14 | 2554-2561 | CI | denotes | placebo |
T15 | 2814-2821 | CI | denotes | placebo |
T16 | 332-343 | CI | denotes | Aflibercept |
T17 | 516-527 | CI | denotes | aflibercept |
T18 | 531-540 | CI | denotes | docetaxel |
T19 | 545-555 | CI | denotes | prednisone |
T2 | 1039-1049 | CI | denotes | prednisone |
T20 | 2070-2081 | CI | denotes | aflibercept |
T21 | 2524-2535 | CI | denotes | aflibercept |
T22 | 2585-2596 | CI | denotes | Aflibercept |
T23 | 2617-2626 | CI | denotes | docetaxel |
T24 | 2631-2641 | CI | denotes | prednisone |
T25 | 2823-2832 | CI | denotes | Docetaxel |
T26 | 2838-2848 | CI | denotes | prednisone |
T27 | 210-219 | CI | denotes | Docetaxel |
T28 | 225-235 | CI | denotes | prednisone |
T29 | 686-695 | CI | denotes | docetaxel |
T3 | 1109-1120 | CI | denotes | aflibercept |
T30 | 700-710 | CI | denotes | prednisone |
T31 | 315-330 | DP | denotes | prostate cancer |
T32 | 629-644 | DP | denotes | prostate cancer |
T33 | 893-908 | DP | denotes | prostate cancer |
T34 | 2718-2733 | DP | denotes | prostate cancer |
T35 | 147-153 | DP | denotes | VENICE |
T36 | 721-727 | DP | denotes | VENICE |
T4 | 1134-1141 | CI | denotes | placebo |
T5 | 0-11 | CI | denotes | Aflibercept |
T6 | 19-26 | CI | denotes | placebo |
T7 | 47-56 | CI | denotes | docetaxel |
T8 | 61-71 | CI | denotes | prednisone |
T9 | 130-145 | DP | denotes | prostate cancer |
T37 | 780-787 | CI | denotes | placebo |
luoyt2021_800_3
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-11 | CI | denotes | Aflibercept |
T10 | 147-153 | DP | denotes | VENICE |
T11 | 721-727 | DP | denotes | VENICE |
T12 | 315-330 | DP | denotes | prostate cancer |
T14 | 893-908 | DP | denotes | prostate cancer |
T15 | 2718-2733 | DP | denotes | prostate cancer |
T16 | 2823-2832 | CI | denotes | Docetaxel |
T17 | 2617-2626 | CI | denotes | docetaxel |
T18 | 979-988 | CI | denotes | docetaxel |
T19 | 686-695 | CI | denotes | docetaxel |
T2 | 2585-2596 | CI | denotes | Aflibercept |
T20 | 531-540 | CI | denotes | docetaxel |
T21 | 210-219 | CI | denotes | Docetaxel |
T22 | 47-56 | CI | denotes | docetaxel |
T23 | 2814-2821 | CI | denotes | placebo |
T24 | 2554-2561 | CI | denotes | placebo |
T25 | 2123-2130 | CI | denotes | placebo |
T26 | 1556-1563 | CI | denotes | placebo |
T27 | 1134-1141 | CI | denotes | placebo |
T28 | 780-787 | CI | denotes | placebo |
T29 | 675-682 | CI | denotes | placebo |
T3 | 2524-2535 | CI | denotes | aflibercept |
T30 | 19-26 | CI | denotes | placebo |
T31 | 2838-2848 | CI | denotes | prednisone |
T32 | 2631-2641 | CI | denotes | prednisone |
T33 | 1039-1049 | CI | denotes | prednisone |
T34 | 700-710 | CI | denotes | prednisone |
T35 | 545-555 | CI | denotes | prednisone |
T36 | 225-235 | CI | denotes | prednisone |
T37 | 61-71 | CI | denotes | prednisone |
T4 | 2070-2081 | CI | denotes | aflibercept |
T5 | 1541-1552 | CI | denotes | Aflibercept |
T6 | 1109-1120 | CI | denotes | aflibercept |
T7 | 516-527 | CI | denotes | aflibercept |
T8 | 332-343 | CI | denotes | Aflibercept |
T9 | 130-145 | DP | denotes | prostate cancer |
T38 | 629-644 | DP | denotes | prostate cancer |